WO2006078911A3 - Gitr antibodies for the diagnosis of nsclc - Google Patents

Gitr antibodies for the diagnosis of nsclc Download PDF

Info

Publication number
WO2006078911A3
WO2006078911A3 PCT/US2006/002050 US2006002050W WO2006078911A3 WO 2006078911 A3 WO2006078911 A3 WO 2006078911A3 US 2006002050 W US2006002050 W US 2006002050W WO 2006078911 A3 WO2006078911 A3 WO 2006078911A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
diagnosis
cancers
gitr antibodies
methods
Prior art date
Application number
PCT/US2006/002050
Other languages
French (fr)
Other versions
WO2006078911A2 (en
Inventor
Beverly Teicher
Shrinivas Shankara
Bruce Roberts
Original Assignee
Genzyme Corp
Beverly Teicher
Shrinivas Shankara
Bruce Roberts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Beverly Teicher, Shrinivas Shankara, Bruce Roberts filed Critical Genzyme Corp
Priority to BRPI0606685-2A priority Critical patent/BRPI0606685A2/en
Priority to AU2006206343A priority patent/AU2006206343A1/en
Priority to JP2007552289A priority patent/JP2008527998A/en
Priority to CA002592330A priority patent/CA2592330A1/en
Priority to EP06719028A priority patent/EP1856281A2/en
Publication of WO2006078911A2 publication Critical patent/WO2006078911A2/en
Publication of WO2006078911A3 publication Critical patent/WO2006078911A3/en
Priority to IL184343A priority patent/IL184343A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of cancers, e.g., NSCLC, of epithelial origin, e.g., lung, ovarian, breast, prostate and colon cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of antigens associated with these cancers and malignancies.
PCT/US2006/002050 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc WO2006078911A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0606685-2A BRPI0606685A2 (en) 2005-01-19 2006-01-19 gitr antibodies for diagnosis of nsclc
AU2006206343A AU2006206343A1 (en) 2005-01-19 2006-01-19 GITR antibodies for the diagnosis of NSCLC
JP2007552289A JP2008527998A (en) 2005-01-19 2006-01-19 GITR antibody for diagnosis of NSCLC
CA002592330A CA2592330A1 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc
EP06719028A EP1856281A2 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc
IL184343A IL184343A0 (en) 2005-01-19 2007-07-02 Gitr antibodies for the diagnosis of nsclc

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64534905P 2005-01-19 2005-01-19
US60/645,349 2005-01-19

Publications (2)

Publication Number Publication Date
WO2006078911A2 WO2006078911A2 (en) 2006-07-27
WO2006078911A3 true WO2006078911A3 (en) 2007-06-28

Family

ID=36692925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002050 WO2006078911A2 (en) 2005-01-19 2006-01-19 Gitr antibodies for the diagnosis of nsclc

Country Status (8)

Country Link
EP (1) EP1856281A2 (en)
JP (1) JP2008527998A (en)
CN (1) CN101133167A (en)
AU (1) AU2006206343A1 (en)
BR (1) BRPI0606685A2 (en)
CA (1) CA2592330A1 (en)
IL (1) IL184343A0 (en)
WO (1) WO2006078911A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241992B2 (en) 2007-07-12 2016-01-26 Gitr, Inc. Combination therapies employing GITR binding molecules

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432091T5 (en) 2005-03-25 2022-03-18 Gitr Inc GITR binding molecules and uses thereof
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
KR101566538B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th17 cell and use thereof
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
SG11201610074YA (en) 2014-06-06 2016-12-29 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP5995207B2 (en) * 2014-11-28 2016-09-21 学校法人 学習院 Boron-containing porphyrin derivatives
JP6812364B2 (en) * 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-GITR antibody for cancer diagnosis
EA201891121A1 (en) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
CA3016894A1 (en) * 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
WO2018162376A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Method for discovery of alternative antigen specific antibody variants
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CN109777872B (en) * 2017-11-15 2021-04-02 北京大学 T cell subsets in lung cancer and genes characteristic thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
WO2000050459A1 (en) * 1999-02-24 2000-08-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) * 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6509173B1 (en) * 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) * 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2000050459A1 (en) * 1999-02-24 2000-08-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241992B2 (en) 2007-07-12 2016-01-26 Gitr, Inc. Combination therapies employing GITR binding molecules

Also Published As

Publication number Publication date
BRPI0606685A2 (en) 2009-07-14
WO2006078911A2 (en) 2006-07-27
IL184343A0 (en) 2007-10-31
CN101133167A (en) 2008-02-27
EP1856281A2 (en) 2007-11-21
JP2008527998A (en) 2008-07-31
CA2592330A1 (en) 2006-07-27
AU2006206343A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006078911A3 (en) Gitr antibodies for the diagnosis of nsclc
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
MX355020B (en) Lung cancer biomarkers and uses thereof.
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
IN2013CN01129A (en)
WO2006089212A3 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
WO2006012646A3 (en) Amacr cancer markers
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
MX2012005995A (en) Novel genomic biomarkers for irritable bowel syndrome diagnosis.
GB2478441A (en) Lung cancer biomarkers and uses thereof
MX2010009766A (en) Protease assay.
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
MX347964B (en) Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents.
CA2816991A1 (en) Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
WO2010093742A8 (en) Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
WO2011113047A3 (en) Compositions and methods for characterizing breast cancer
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
PL2211180T3 (en) Use of protein SATB2 as a marker for distinguishing colorectal cancer from other cancers
WO2013036754A3 (en) Methods and compositions for diagnosis of ovarian cancer
WO2011087709A3 (en) Eml4-alk translocations in lung cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680006891.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006206343

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2592330

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 184343

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006719028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008691

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007552289

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006206343

Country of ref document: AU

Date of ref document: 20060119

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2899/KOLNP/2007

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: PI0606685

Country of ref document: BR

Kind code of ref document: A2